Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2853

Innovative Uses of Biofilms for Protein Delivery, Vaccine Development, and Infectious Disease Treatment

Inventors: Paula Watnick

Invention Types: Therapeutics

Research Areas: Gastrointestinal/Nutrition, Immunology, Infectious Disease

Keywords: Drug Delivery

For More Information Contact:  Meyer, Abbie

 

Invention Description:

A biofilm is a microbial community attached to various biological or non-biological surfaces and is held in place by an extracellular matrix. Biofilms are implicated in many disorders of human health, and a deeper understanding of biofilms may allow them to be engineered for biomedical applications.


The lab of Dr. Paula Watnick, MD, PhD, at Boston Children’s Hospital has developed an innovative use of biofilms as a flexible platform for protein delivery and vaccine development. The researchers showed that functional enzymes can be fused to RbmA, a protein in the biofilm extracellular matrix. RbmA plays in an important role in multilayer biofilm formation and Dr. Watnick has observed that its main function, recruiting new cells to the biofilm, is initiated after it undergoes a proteolytic event which results in RbmA*, and is different than most extracytoplasmic proteases that cause biofilm dispersion rather than formation.
Furthermore, researchers were able to utilize biofilms to present and concentrate proteins and antigens at various biotic and abiotic surfaces. Currently, this technique is being used to develop a general diarrheal disease vaccine.|

The Watnick lab additionally studied the molecular composition of biofilms in order to give new insights into how biofilms can be disrupted in disease treatment. Researchers identified a peptide fragment produced by the proteolytic enzymes HAP, PrtV and VC0157, and they further showed that this fragment recruits additional bacteria to the biofilm surface which did not involve RbmA. This finding suggests that novel inhibitors targeting HAP, PrtV or VC0157 could be developed to help block biofilm expansion.

Applications:

Vaccine development:

• A platform that utilizes bacterial biofilms as a means for presenting and concentrating antigens at surfaces for vaccine development.


Therapeutics delivery:

• A platform to deliver therapeutics directly to the site of V. cholera infections in the GI tract; Therapeutic enzymes or small molecules can be conjugated to or targeted toward Bap1, RbmA or RbmC and delivered to biofilms.
• Delivery of enzyme therapeutics directly to the site of other biofilm infections via intravenous or intramuscular routes by fusing the enzymes of interest to Bap1 or RbmC.

Biofilm disruption:
• Development of pharmacological inhibitors of HAP, PrtV and VC0157 to block recruitment of additional bacteria to existing biofilms. Such inhibitors could be used to treat patient infections or to disinfect surfaces.

Competitive Advantages:

• Enables targeted delivery of proteins to biotic and abiotic surfaces through an inexpensive, genetically tractable model.

• Genetic approach to overexpress matrix-conjugated enzymes in V. cholera is self-renewing, as opposed to biochemical or in vitro methods.

• Provides flexibility to genetically conjugate single or multiple antigens of interest to Bap1, RbmA or RbmC for the purpose of vaccine development.|
• By using multiple antigens in this vaccine-development platform, this technology could enable generation of vaccines with broader specificity and the ability to protect against multiple diseases at once.

• Has potential to improve the protective coverage of vaccines with minimal changes to cost, administration and storage.

Business Opportunity:

Non-exclusive license or exclusive license by field or sponsored research opportunity.

Key Publications: Smith DR, Maestre-reyna M, Lee G, Gerard H, Wang AH, Watnick PI. (2015). In situ proteolysis of the Vibrio cholerae matrix protein RbmA promotes biofilm recruitment. Proc Natl Acad Sci USA.;112(33): doi: 10.1073/pnas.1512424112.


Absalon C, Ymele-Leki P, Watnick PI, (2012). The Bacterial Biofilm Matrix as a Platform for Protein Delivery. mBio 3(4): doi:10.1128/mBio.00127-12.


Absalon C, Ymele-Leki P, Watnick PI, (2012). The Bacterial Biofilm Matrix as a Platform for Protein Delivery. mBio 3(4): doi:10.1128/mBio.00127-12.


Absalon C, Van Dellen K, Watnick PI (2011). A Communal Bacterial Adhesin Anchors Biofilm and Bystander Cells to Surfaces. PLoS Pathog 7(8): e1002210. doi:10.1371/journal.ppat.1002210.

IPStatus: Pat. Pend.